Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT02457962
- Status
- Recruiting
Conditions
- Hematologic Malignancies
- Solid Tumors
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
To collect and analyze specimens that will correlate with clinical outcomes such as acute and late toxicities, quality of life, local control, and survival of patients treated with photon/proton therapy.
Key Dates
- Start date
- Apr 23, 2015
- Status verified
- Mar 2026
- Primary completion
- Apr 30, 2031
- Completion
- Apr 30, 2031
Study Design
- Enrollment
- 15,000 participants (estimated)
Primary Outcome Measure
analyze acute and late toxicities using CTCAE 4.03 [ Time Frame: Patients will be followed for the duration of their life, an expected average of 20 years ]
Central Contacts
- Clinical Trials Referral Office855-776-0015
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | Clinical Trials Referral Office 855-776-0015 Nadia N. Laack, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Rochester, MN
By research site
Related Studies
- CIBMTR Research DatabaseRecruiting · Center for International Blood and Marrow Transplant Research · Minneapolis, Minnesota
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)Recruiting · Center for International Blood and Marrow Transplant Research · Birmingham, Alabama
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)PHASE3 · Recruiting · Merck Sharp & Dohme LLC · Tucson, Arizona
- Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Springdale, Arkansas